International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(24), P. 17187 - 17187
Published: Dec. 6, 2023
Cancer is rooted in genetic background, with the expression of oncogenesis playing a pivotal role early stages tumor formation [...].
Language: Английский
Diseases, Journal Year: 2025, Volume and Issue: 13(1), P. 24 - 24
Published: Jan. 20, 2025
Background: Cancer remains a leading cause of morbidity and mortality worldwide. Traditional treatments like chemotherapy radiation often result in significant side effects varied patient outcomes. Immunotherapy has emerged as promising alternative, harnessing the immune system to target cancer cells. However, complexity responses tumor heterogeneity challenges its effectiveness. Objective: This mini-narrative review explores role artificial intelligence [AI] enhancing efficacy immunotherapy, predicting responses, discovering novel therapeutic targets. Methods: A comprehensive literature was conducted, focusing on studies published between 2010 2024 that examined application AI immunotherapy. Databases such PubMed, Google Scholar, Web Science were utilized, articles selected based relevance topic. Results: significantly contributed identifying biomarkers predict immunotherapy by analyzing genomic, transcriptomic, proteomic data. It also optimizes combination therapies most effective treatment protocols. AI-driven predictive models help assess response guiding clinical decision-making minimizing effects. Additionally, facilitates discovery targets, neoantigens, enabling development personalized immunotherapies. Conclusions: holds immense potential transforming related data privacy, algorithm transparency, integration must be addressed. Overcoming these hurdles will likely make central component future offering more treatments.
Language: Английский
Citations
1
Cancer Letters, Journal Year: 2024, Volume and Issue: 593, P. 216960 - 216960
Published: May 17, 2024
Extracellular vesicles (EVs) have been the subject of an exponentially growing number studies covering their biogenesis mechanisms, isolation and analysis techniques, physiological pathological roles, clinical applications, such as biomarker therapeutic uses. Nevertheless, heterogeneity EVs both challenges our understanding them presents new opportunities for potential application. Recently, EV field experienced a wide range advances. However, also remain huge. This review focuses on recent progress difficulties encountered in practical use settings. In addition, we explored concept to acquire more thorough involvement cancer, specifically focusing fundamental nature EVs.
Language: Английский
Citations
6
Toxicology Reports, Journal Year: 2024, Volume and Issue: unknown, P. 101732 - 101732
Published: Sept. 1, 2024
Language: Английский
Citations
5
Expert Review of Molecular Diagnostics, Journal Year: 2024, Volume and Issue: 24(4), P. 299 - 310
Published: Feb. 5, 2024
Introduction Tumor-infiltrating lymphocytes (TILs) have been investigated as prognostic factors in melanoma. Recent advancements assessing the tumor microenvironment setting of more widespread use immune checkpoint blockade reignited interest identifying predictive biomarkers. This review examines function and significance TILs cutaneous melanoma, evaluating their potential markers.
Language: Английский
Citations
4
Molecular Oncology, Journal Year: 2024, Volume and Issue: 18(4), P. 969 - 987
Published: Feb. 7, 2024
Immunotherapies for malignant melanoma seek to boost the anti‐tumoral response of CD8 + T cells, but have a limited patient rate, in part due tumoral immune cell infiltration. Genetic or pharmacological inhibition pannexin 1 (PANX1) channel‐forming protein is known decrease tumorigenic properties vitro and ex vivo . Here, we crossed Panx1 knockout ( −/− ) mice with inducible model Braf CA , Pten loxP Tyr::CreER T2 (BPC). We found that deleting gene does not reduce BRAF(V600E)/Pten‐driven primary tumor formation improve survival. However, tumors BPC‐ exhibited significant increase infiltration lymphocytes, no changes expression early T‐cell activation marker CD69, lymphocyte 3 (LAG‐3) checkpoint receptor, programmed death ligand‐1 (PD‐L1) when compared +/+ genotype. Our results suggest that, although deletion overturn aggressive BRAF / ‐driven progression it effector populations microenvironment. propose PANX1‐targeted therapy could be explored as strategy tumor‐infiltrating lymphocytes anti‐tumor immunity.
Language: Английский
Citations
4
Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: Jan. 22, 2025
Cutaneous melanoma is one of the most aggressive skin cancers originating from pigment cells. Patients with advanced suffer a poor prognosis and generally cannot benefit well surgical resection chemo/target therapy due to metastasis drug resistance. Thus, adoptive cell (ACT), employing immune cells specific tumor-recognizing receptors, has emerged as promising therapeutic approach display on-tumor toxicity. This review discusses application, efficacy, limitations, future prospects four commonly utilized approaches -including tumor-infiltrating lymphocytes, chimeric antigen receptor (CAR) T cell, engineered T-cell cells, NK cells- in context malignant melanoma.
Language: Английский
Citations
0
Expert Review of Molecular Diagnostics, Journal Year: 2024, Volume and Issue: 24(5), P. 379 - 392
Published: May 3, 2024
Over the past decade, significant advancements in field of melanoma have included introduction a new staging system and development immunotherapy targeted therapies, leading to changes substage classification impacting patient prognosis. Despite these strides, early detection remains paramount. The quest for dependable prognostic biomarkers is ongoing, given melanoma's unpredictable nature, especially identifying patients at risk relapse. Reliable are critical informed treatment decisions.
Language: Английский
Citations
3
Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: 397(12), P. 9227 - 9241
Published: July 2, 2024
Language: Английский
Citations
1
Health Science Reports, Journal Year: 2024, Volume and Issue: 7(7)
Published: July 1, 2024
Abstract Background and Aims The tumor microenvironment (TME) exerts an important role in carcinogenesis progression. Several investigations have suggested that immune cell infiltration (ICI) is of high prognostic importance for progression patient survival many tumors, particularly prostate cancer. pattern PCa, on the other hand, has not been thoroughly understood. Methods Cancer Genome Atlas (TCGA) Gene Expression Omnibus (GEO) datasets PCa were obtained, several merged into one data set using “ComBat” algorithm. ICI profiles patients then to be uncovered by two computer techniques. unsupervised clustering method was utilized identify three patterns samples, Principal Component Analysis (PCA) conducted estimate score. Results Three different clusters ICIs identified 1341 which also correlated with clinical features/characteristics biological pathways. Patients are classified low subtypes based scores extracted from immune‐associated signature genes. High score associated a worse prognosis, may intrigue activation cancer‐related immune‐related pathways such as involving Toll‐like receptors, T‐cell JAK‐STAT, natural killer cells. linked mutation load immune/cancer‐relevant signaling pathways, explain cancer's poor prognosis. Conclusion findings this study only advanced our knowledge mechanism response but provided novel biomarker, is, score, disease prognosis guiding precision immunotherapy.
Language: Английский
Citations
1
Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(16)
Published: Aug. 1, 2024
Immune-checkpoint inhibitors are now used more commonly in combination than monotherapy as the first-line choice patients with unresectable advanced melanoma. Nevertheless, for cases that progressed after initial therapy, subsequent regimen option can be very difficult. Herein, we reported efficacy and safety of a triple Chinese melanoma who had poor responses to immune therapy.
Language: Английский
Citations
1